Share |
18 May 2021


Leading European researchers take stock on innovative study on diabetic retinopathy

amb eyedropPartners of EUROCONDOR - the European consortium for the early treatment of diabetic retinopathy - gathered in Barcelona on 25 May 2013 for their 3rd annual meeting to take stock of the advancement of the 4-year research project.

EUROCONDOR, an EU-funded research project set up with the 7th Framework Programme (FP7), brings together a group of 17 leading research and field partners across Europe, including a biopharmaceutical SME and IDF Europe. The consortium is carrying out a clinical trial to evaluate the safety and effectiveness of an innovative therapeutic treatment using eye drops for the early stages of diabetic retinopathy.

The 2013 annual meeting was the opportunity for project partners to take stock on the advancement of the project. The EUROCONDOR clinical trial started in February this year. As a partner, IDF Europe is liaising with national and local diabetes associations to seek ways of promoting the research project to local diabetes communities and build synergies with the clinical centres taking part in the research.

Diabetic retinopathy is an eye disease that occurs in people living with diabetes. It involves changes in the tiny blood vessels that nourish the retina at the back of the eye which can ultimately lead to severe loss of vision or even blindness. Today, diabetic retinopathy is the leading cause of preventable blindness among working-age individuals in developed countries.

Along with the human suffering from this devastating complication comes an increasingly heavy economic burden: healthcare costs for patients with diabetic retinopathy are almost double that of patients without the complication.

For more information about the EUROCONDOR project, visit the project's website or contact Gael Bassetto at This email address is being protected from spambots. You need JavaScript enabled to view it.